Showing 2351-2360 of 9355 results for "".
- GLP-1 Receptor Agonists Show Complex, Evolving Role in Alopecia Areatahttps://practicaldermatology.com/news/glp-1-receptor-agonists-show-complex-evolving-role-in-alopecia-areata/2486415/The emerging and sometimes contradictory relationship between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and hair disorders, particularly alopecia areata, was the subject of a talk by Natasha Atanaskova Mesinkovska, MD, PhD, at the 2026 American Academy of Dermatology (AAD) Annual Meet
- ICONIC-LEAD: Durable Psoriasis Clearance Through 52 Weeks with Icotrokinrahttps://practicaldermatology.com/news/new-icotrokinra-data-shows-durable-psoriasis-clearance-through-52-weeks/2486414/The US Food and Drug Administration (FDA) recently granted approval for the oral interleukin (IL)-23 receptor antagonist icotrokinra (ICOTYDE™, Johnson & Johnson) for patients aged 12 years and older with moderate-to-severe plaque psoriasis who are candidates f
- Prospective Data Show Comparable Performance Between AI and Dermatologistshttps://practicaldermatology.com/news/prospective-data-show-comparable-performance-between-ai-and-dermatologists/2486375/A new systematic review and meta-analysis of prospective studies suggests artificial intelligence (AI) systems can achieve diagnostic performance comparable to dermatologists in melanoma detection using dermoscopy. Investigato
- New Grants Expand Teledermatology Access in the Bronx and Los Angeleshttps://practicaldermatology.com/news/new-gwpfizer-grants-expand-teledermatology-access-in-the-bronx-and-los-angeles/2486357/The George Washington University School of Medicine (GW) and Health Sciences, in collaboration with Pfizer Global Medical Grants, has awarded 2 new grants to expand teledermatology services in underserved US communities, with 2026 programs set for the Bronx and Los
- Study: Potential Link Between Lesional IgG Autoantibodies and HS Disease Severityhttps://practicaldermatology.com/news/study-suggests-potential-link-between-lesional-igg-autoantibodies-and-hs-disease-severity/2486348/A small biopsy-based study in the Journal of Investigative Dermatology Innovations adds to emerging evidence that humoral immunity may contribute to hidradenitis suppurativa (HS) pathobiology. Investigators analyzed
- Analysis: Long Waits for Pediatric Dermatology Appointments Across UShttps://practicaldermatology.com/news/study-finds-long-waits-for-pediatric-dermatology-appointments-across-us/2486313/Children seeking dermatologic care in the US face long waits regardless of where they are referred, according to a research letter published online in JAMA Dermatology. Using a mystery caller design, investigators as
- INTEGUMENT-OLE Data Show Sustained Efficacy of Roflumilast in Early Childhood ADhttps://practicaldermatology.com/news/integument-ole-data-show-sustained-efficacy-of-roflumilast-in-early-childhood-ad/2486045/The 56-week phase 3 open-label extension for the INTEGUMENT trial (INTEGUMETN-OLE) indicated once-daily roflumilast cream 0.05% maintained efficacy and demonstrated favorable long-term safety in children aged 2 to 5 years with mild-to-moderate atopic dermatitis (AD
- Sotyktu Gets FDA Nod as First TYK2 Inhibitor for Psoriatic Arthritishttps://practicaldermatology.com/news/sotyktu-gains-fda-approval-as-first-tyk2-inhibitor-for-psoriatic-arthritis/2486046/The US Food and Drug Administration (FDA) has approved deucravacitinib (Sotyktu; Bristol Myers Squibb) for the treatment of adults with active psoriatic arthritis (PsA), representing the first oral therapy in its class approved for the treatment of the condition, a
- Baricitinib, Ritlecitinib, and Deuruxolitinib Demonstrate Efficacy in Severe AAhttps://practicaldermatology.com/news/baricitinib-ritlecitinib-and-deuruxolitinib-demonstrate-efficacy-in-severe-aa/2485957/An analysis of clinical trials reports that Janus kinase (JAK) inhibitors shows significant efficacy and manageable safety profiles in treating severe alopecia areata (AA). Alopecia areata (AA) is an autoimmune disorder charac
- Arcutis Launches First-in-Human Trial of CD200R Agonist ARQ-234 in Atopic Dermatitishttps://practicaldermatology.com/news/arcutis-launches-first-in-human-trial-of-cd200r-agonist-arq-234-in-atopic-dermatitis/2485894/Arcutis Biotherapeutics announced today that it has enrolled the first participant in a phase 1a/1b clinical trial evaluating ARQ-234, an investigational CD200 receptor (CD200R) agonist, in healthy volunteers and adults with moderate to severe atopic dermatitis (AD